Invex Therapeutics (ASX:IXC) Other Operating Expense: A$0.26 Mil (TTM As of Dec. 2025)


What is Invex Therapeutics Other Operating Expense?

Invex Therapeutics ASX:IXC Other Operating Expense is A$0.26 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Invex Therapeutics's Other Operating Expense for the six months ended in Dec. 2025 was A$0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.26 Mil.

Invex Therapeutics's quarterly Other Operating Expense increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.26 Mil) but then declined from Jun. 2025 (A$0.26 Mil) to Dec. 2025 (A$0.00 Mil).

Invex Therapeutics's annual Other Operating Expense increased from Jun. 2023 (A$0.29 Mil) to Jun. 2024 (A$0.45 Mil) but then declined from Jun. 2024 (A$0.45 Mil) to Jun. 2025 (A$0.26 Mil).

Invex Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Other Operating Expense Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Operating Expense
Get a 7-Day Free Trial 0.31 0.38 0.29 0.45 0.26

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.45 0.00 0.26 0.00

Invex Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of A$0.26 Mil mean?
Invex Therapeutics (ASX:IXC) has a Other Operating Expense of A$0.26 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Other Operating Expense too high?
Invex Therapeutics' current Other Operating Expense is A$0.26 Mil.
How does Invex Therapeutics' Other Operating Expense compare to VRTX and REGN?
Invex Therapeutics' Other Operating Expense of A$0.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Other Operating Expense is A$0.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Other Operating Expense of A$0.26 Mil. The current Other Operating Expense is A$0.26 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Other Operating Expense is A$0.26 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.